Jafron Haemoadsorption During Cardiopulmonary Bypass

• Status: Not yet recruiting
• Trial end date: 2022-09-15
• Target enrollment: 0
• Participant gender: All

Summary

Cardiopulmonary bypass (CPB) is often associated with degrees of complex inflammatory response mediated by various cytokines. This response can, in severe cases, lead to systemic hypotension and organ dysfunction. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. Jafron is a device designed to remove cytokine from the blood using haemoadsorption (HA). This preliminary report aims to evaluate the potential of Jafron to decrease peri-operative cytokine levels in cardiac surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Anthea Hospital Bari

Criteria

Inclusion Criteria :

• elective cardiac surgery under CPB

• double valve replacement or a complex surgery with an expected CPB duration > 120 min

• redo cardiac surgery

Exclusion criteria:

• end-stage renal disease (dialysis dependence)

• active infectious endocarditis

• emergency or off-pump procedure

• prescription of non-steroidal antiinflammatory medication (except for low-dose aspirin) or corticosteroids within 7 days

• enrolment in another conflicting study

• administration of human albumin during CPB